From: Notalgia paresthetica: clinical features, radiological evaluation, and a novel therapeutic option
NP group (n:45) | Control group (n:35) | P value | |
---|---|---|---|
Female (n)(%) | 39 (87%) | 21 (60%) | < 0.001 |
Male (n) (%) | 6 (13%) | 14 (40%) | |
Age (years) (mean ± SD) (min-max) | 54.7 ± 12.2 (27–77) | 56.8 ± 10.4 | 0.64 |
BMI (kg/m2) (mean ± SD) | 29.9 ± 1.8 | 27.8 ± 2.0 | 0.39 |
Duration of Symptoms (months)(Median) (min-max)(IQR) | 12 (1–240) (33) | 10 (2–190) (29) | 0.28 |
VAS-pain (Median) (min-max)(IQR) | 8 (5–10) (2) | 7 (3–9)(2) | 0.55 |
VAS-pruritus (Median) (min-max)(IQR) | 6 (0–9) (7) | – | |
Dermatomal Localization (n)(%) | – | ||
Right | 18 (40%) | ||
Left | 24 (53%) | ||
Bilateral | 3 (7%) | ||
Clinical findings (n)(%) | – | ||
Pruritus | 45 (100%) | ||
Burning | 22 (49%) | ||
Paresthesia | 20 (44%) | ||
Hypoesthesia | 18 (40%) | ||
Prickling | 14 (31%) | ||
Tingling | 7 (16%) | ||
Hyperesthesia | 3 (7%) | ||
Coldness | 2 (4%) |